Skip to main content
. 2017 Oct 31;8(63):107022–107032. doi: 10.18632/oncotarget.22206

Figure 2. The DFS and OS in the patients front-line treated with the 1st- and 2nd-generation TKIs.

Figure 2

An apparently, though not significantly, better DFS was observed in patients being treated with the 2nd-generation TKIs compared with that in the 1st-generation TKI group (A, P= 0.088). The OS was comparable between the two groups (B, P=0.210).